Drug-Drug Interactions with Antipsychotics

CNS Spectrums

Volumn 12, Issue S21, 2007, Pages 6-9

  Meyer, Jonathan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; NEUROLEPTIC AGENT;

DRUG EFFECT; DRUG INTERACTION; HUMAN; METABOLISM; POLYPHARMACY; PROFESSIONAL COMPETENCE; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; POLYPHARMACY; PROFESSIONAL COMPETENCE; SCHIZOPHRENIA;

EID: 42949105566     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900015947     Document Type: Article

References (24)

1. Budnitz, DS, Pollock, DA, Weidenbach, KN, et al. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006; 296(15):1858–1866.
2. Clark, RE, Bartels, SJ, Mellman, TA, Peacock, WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull. 2002; 28(1):75–84.
3. Chakos, MH, Glick, ID, Miller, AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv. 2006; 57(8):1094–1101.
4. Lizer, MH, Brackbill, ML. Medication history reconciliation by pharmacists in an inpatient behavioral health unit. Am J Health Syst Pharm. 2007; 64(10): 1087–1091.
5. Cozza, KL, Armstrong, SC, Oesterheld, JR. Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450s, Ugts, P-Glycoproteins. 2nd ed. Washington, DC: American Psychiatric Press, Inc.; 2003.
6. Richelson, E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc. 1997; 72(9):835–847.
7. Olesen, OV, Linnet, K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol. 2001; 41: 823–832.
8. Meyer, JM. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol. 2001: 21(6):569–574.
9. Preskorn, SH, Flockhart, D. 2006. Guide to psychiatric drug interactions. Primary Psychiatry. 2006: 13: 35–64.
10. Flockhart, DA. Available at: http://medicine.iupui.edu/flockhart/table.htm. Accessed September 21, 2007.
11. Abilify [Package Insert]. Princeton, NJ: Bristol-Myers Squibb; 2006.
12. Clozaril [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2005.
13. Zyprexa [Package Insert]. Indianapolis, IN: Eli Lilly; 2006.
14. Joos, AA, König, F, Frank, UG, et al. Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer. Pharmacopsychiatry. 1997; 30(6):266–270.
15. Olesen, OV, Linnet, K. Fluvoxamine-Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol. 2000; 20(1):35–42.
16. Rostami-Hodjegan, A, Amin, AM, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004; 24(1):70–78.
17. Seroquel [Package Insert]. Wilmington, Del: Astra Zeneca Pharmaceuticals LP; 2005.
18. DeVane, CL, Nemeroff, CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001; 40(7):509–522.
19. Risperdal [Package Insert]. Titusville, NJ: Janssen Pharmaceutica; 2006.
20. Wong, YW, Yen, C, Thyrum, PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol. 2001; 21(1):89–93.
21. Spina, E, Avenoso, A, Scordo, MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol. 2002; 22(4):419–423.
22. Invega [Package Insert]. Titusville, NJ: Janssen Pharmaceutica; 2006.
23. Geodon [Package Insert]. New York, NY: Pfizer Inc., 2006.
24. Preskorn, SH. Drug-drug interactions: proof of relevance (part II) cause of tolerability problems or noncompliance. J Psychiatr Pract. 2005; 11(6):397–401.